Transiently produced IgGs enable infection-blocking vaccine efficacy assessment
International Immunology · 10.07.2026
DOI: 10.1093/intimm/dxag035 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunology, online erschienen am 10.07.2026. Verfasst von Jingzhi Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China. Die Arbeit nennt 25 Literaturangaben. Gefördert von: National Key R&D Programs of China.
Abstract (Originalsprache)
Many vaccines are evaluated based on their ability to prevent symptoms, rather than infection itself, limiting their effectiveness in controlling asymptomatic transmission and achieving viral eradication. Here, we aimed to develop a serology-based strategy to detect asymptomatic infections and quantify the duration of infection-blocking protection, thereby enabling data-driven revaccination and offering a complementary framework for future infection-blocking vaccine efficacy (VE) evaluation. Using porcine circovirus 2 vaccines as a model, we identified that anti-peptide IgGs appear transiently after vaccination but are reproducibly reinduced upon post-vaccination infection, whereas anti-Capsid protein IgGs persist over time. This distinct serological response enables detection of new infections post-vaccination. By analysing anti-peptide IgG response patterns across multiple sampling time points, we defined a digital microarray index (DMI) that captured the duration of vaccine-induced protection, and successfully ranked the infection-blocking efficacy of five commercial vaccines. Application to single-day samples from eight farms demonstrated that DMI, when paired with vaccination timing, accurately determined herd-level immune status and informed rational revaccination scheduling. This study introduces a serological platform for detecting asymptomatic infections and quantifying infection-blocking protection. The DMI enables high-resolution immune surveillance, informs timely revaccination, and lays the groundwork for future VE trials targeting infection-blocking and pathogen elimination.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou, 215123, China.
- Suzhou Qiangdong Biotechnology Co. Ltd., Suzhou, 215123, China.
- China Institute of Veterinary Drug Control, Beijing, 100081, China.
- Suzhou animal husbandry and veterinary station, Suzhou, 215007, China.
ORCID-Profile: Hongwei Ma
Förderung
- National Key R&D Programs of China
Zitieren
APA
Li, J., Gu, C., Chen, X., Sheng, S., Xue, Q., & Ma, H. (2026). Transiently produced IgGs enable infection-blocking vaccine efficacy assessment. International Immunology. https://doi.org/10.1093/intimm/dxag035
Vancouver
Li J, Gu C, Chen X, Sheng S, Xue Q, Ma H. Transiently produced IgGs enable infection-blocking vaccine efficacy assessment. International Immunology. 2026. doi:10.1093/intimm/dxag035
BibTeX
@article{Li2026,
author = {Li, Jingzhi and Gu, Chaoyi and Chen, Xiaochun and Sheng, Shuixing and Xue, Qinghong and Ma, Hongwei},
title = {Transiently produced IgGs enable infection-blocking vaccine efficacy assessment},
journal = {International Immunology},
year = {2026},
doi = {10.1093/intimm/dxag035}
}
EUVIMED